GSK wins US approval for hepatitis B drug as Hutchmed deal closes
(Alliance News) - GSK PLC on Wednesday announced US regulatory approval for its chronic hepatitis B treatment Hibsago, while Hutchmed China Ltd confirmed the completion of a separate licensing agreement with GSK worth up to USD1.30 billion. Read More